German pharmaceutical giant Merck's life science division, EMD Millipore, has launched its 'single-use' Mobius 3L CellReady Bioreactor, for use in the development and optimisation of cell culture processes.
The firm claims the bioreactor allows “operational flexibility and enhanced process monitoring capabilities,” enabling perfusion and the monitoring of additional cell culture parameters, such as carbon dioxide, viable cell density or optical density.
The new model differs from previous models in three distinct ways: the Mobius 3L features an injection port for the addition of small volumes, a sub-surface fluid port for either addition or removal, and an additional port for insertion of a third probe.
The company say the Mobius 3L offers 'out-of-the-box' convenience, helping eliminate time spent on cleaning, assembly and sterilisation.
As a consequence, EMD claim the new bioreactor can reduce the turnaround time typically associated with glass models.